7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
A deep dive into how the mitochondrial peptide MOTS-c affects adolescent development, metabolism, and safety in ages 12 to 17, with primary-source citations and a clear framework for clinical decision-making.
A guide to MOTS-c use in adults 65 and older, covering physical activity integration, cognitive engagement, dosing context, safety signals, and evidence from human and animal trials.
A guide to off-label MOTS-c use in geriatric patients, covering the mitochondrial biology, available human and animal data, dosing protocols, safety signals, and what to discuss with your prescribing provider.
MOTS-c is an experimental mitochondrial peptide with zero pediatric clinical trial data. This evidence review explains why off-label use in children under 12 carries serious unknowns and what the current science actually shows.
A guide to MOTS-c mitochondrial peptide in pediatric patients under 12, covering current evidence, safety data, regulatory status, and what a structured transition to adult endocrinology care looks like.
A guide to MOTS-c use in children under 12, covering school performance, physical activity, mitochondrial biology, and the complete absence of pediatric safety data.
A thorough clinical review of MOTS-c mitochondrial peptide use in children under 12, covering developmental biology, current evidence, safety concerns, and why no pediatric dosing protocol exists yet.